



News Release

PIVOTAL THERAPEUTICS ANNOUNCES THIRD QUARTER FINANCIAL RESULTS AND EXECUTES DISTRIBUTION AGREEMENT

FOR IMMEDIATE RELEASE

November 30, 2015

Woodbridge, Ontario, November 30, 2015 - Pivotal Therapeutics Inc. (OTCQB: PVTTF) (CSE: PVO), a specialty pharmaceutical company with a focus on Omega-3 therapies for cardiovascular disease (CVD) and overall health, announced its operational highlights and financial results for the nine months ended September 30, 2015. All dollar amounts referenced herein are in Canadian dollars unless otherwise stated.

Additionally, the Company executed an international exclusive distribution agreement for **BeneFishial™ Pet** in the Republic of Korea with Healthcore Co. Ltd., an affiliate of Korean Animal Medical Science Institute (KAMSI).

Operational Highlights for Q3 2015:

- Issuance of Patent Number **9,119,826** titled "Omega-3 Fatty Acid For Use As a Prescription Medical Food And Omega-3 Fatty Acid Diagnostic Assay For The Dietary Management Of Cardiovascular Patients with Cardiovascular Disease (CVD) Who Are Deficient In Blood EPA and DHA Levels."
- Received Notice of Allowance for Pivotal's U.S. Patent Application Serial Number 14/594,095 entitled "Process and Composition For Stabilization of Vulnerable Plaque Utilizing a Combination of a Statin and Omega 3 Fatty Acids."
- Announced equity financing to raise up to \$1,500,000 CDN through a non-brokered private placement of up to 7,500,000 units at a price of \$0.21 per Unit.
- Publication of a research article entitled "Oxidation levels of North American over-the-counter *n-3* (omega-3) supplements and the influence of supplement formulation and delivery form on evaluating oxidative safety." http://journals.cambridge.org/repo_A99uJU/rER5dac
- **BeneFishial™ Pet** Formulation Approved for Sale in Canada, received Notification Number **NN.F7C1** for **BeneFishial™ Pet** from the Low Risk Veterinary Health Products Interim Notification Program (LRVHP).
- Closed the first tranche of the previously announced non-brokered private placement consisting of 476,196 Units for gross proceeds of \$100,000 CDN.

Financial Results

For the nine months ended September, 2015 the Company reported an increase in sales of 88% to \$373,787 (\$198,867 – 2014), a decrease in operating expenses of 52% to \$2,274,944 (\$4,698,592– 2014)



and a decrease of 32% in net loss to \$3,706,876 (\$5,418,497 – 2014).

The audited consolidated financial statements, accompanying notes thereto and Management's Discussion and Analysis for the nine months ended September 30, 2015, will be accessible on SEDAR www.sedar.com, CSE www.cnsx.ca under the symbol "PVO" and OTCQB www.otcqx.com under the symbol "PVTTF".

About Pivotal Therapeutics Inc.

Pivotal Therapeutics is a publicly traded (**OTCQB:PVTTF; CSE:PVO**), specialty pharmaceutical company with a focus on cardiovascular disease and overall health. Pivotal Therapeutics' lead product **VASCAZEN**[®] is a prescription only medical food specially formulated for the dietary management of Omega-3 deficiency in patients with cardiovascular disease through elevating Eicosapentaenoic acid (EPA) and Docosahexaenoic acid (DHA) to levels associated with reduced risk of cardiovascular complications. **OMAZEN**[®] is a pharmaceutical grade Omega-3 providing over 90% pure Omega-3 in each capsule for the maintenance of good health. **OMAZEN**[®] is a patented product available for sale and distribution in Canada for the professional market. **BeneFishial**[™] and **BeneFishial**[™] **Pet** are the first products in Pivotal's new nutraceutical product line, which is specifically designed to be sold in the OTC direct-to-retail or direct-to-consumer markets and animal health and nutrition markets. The Company's product line is being expanded to include its first drug candidate **PVT-100** and a point-of-care diagnostic **OmegaSTAT**[™]. **PVT-100** utilizes **VASCAZEN**[®]'s unique formulation for the stabilization of vulnerable plaque in patients undergoing carotid endarterectomy. **OmegaSTAT**[™] is a rapid format point-of-care (POC) diagnostic test being developed to measure Omega-3 deficiency.

Disclosure Notice

The information contained in this document is as of November 30, 2015. This press release contains forward-looking statements. Such forward-looking statements are subject to a number of risks, assumptions and uncertainties that could cause Pivotal's actual results to differ materially from those projected in such forward-looking statements. These statements can be identified by the use of words such as "will", "anticipate", "estimate", "expect", "project", "forecast", "intend", "plan", "believe", "project", "potential", and similar expressions with any discussion of future operating or financial performance or events. In particular, factors that could cause actual results to differ materially from those in forward looking statements include the following: Pivotal's ability to obtain additional financing on acceptable terms; growth in costs and expenses; ability to compete with others who provide comparable products; risk that the Company's products will not gain widespread market acceptance. Forward-looking statements speak only as of the date made and are not guarantees of future performance. The Company undertakes no obligation to publicly update or revise any forward-looking statements contained in this document as a result of new information or future events or developments. The CSE has not reviewed and does not accept responsibility for the adequacy or accuracy of this information.

- # -

Company Contacts:

Kristine DiMatteo
Communications and Public Relations Manager
Phone: 905-856-9797 ext. 231
E-Mail: kdimatteo@pivotaltherapeutics.us

www.pivotaltherapeutics.us